THE USE OF PHYSOSTIGMINE BY TOXICOLOGISTS IN ANTICHOLINERGIC TOXICITY

Joseph W Watkins MD1, Evan S Schwarz MD1, Anna M Arroyo-Plasencia MD2, on behalf of the Toxicology Investigators Consortium
1Division of Emergency Medicine, Washington University School of Medicine, St. Louis, Missouri
2Department of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri

INTRODUCTION
• The anticholinergic toxidrome is well described and relatively common.
• Administration of physostigmine is generally regarded as the antidote to anticholinergic toxicity.
• Physicians without toxicology training may be reticent to use physostigmine due to their unfamiliarity.
• We would expect that trained Toxicologists would be relatively liberal in its use.

RESEARCH QUESTION
• How often is physostigmine administered to patients with anticholinergic toxicity that are evaluated by a Toxicologist?

RESULTS
• The review included 815 patients from January of 2012 through March of 2014.
• Of the patients who received physostigmine alone, 2 (1.9%) required intubation and 6 (5.9%) developed rhabdomyolysis.
• Of those who received benzodiazepines alone, 27 (11.9%) required intubation and 0 (0%) developed rhabdomyolysis.
• Of those who received a combination of physostigmine and benzodiazepines, 9 (12.5%) required intubation and 5 (6.9%) developed rhabdomyolysis.
• Of those who did not receive physostigmine, 54 (8.4%) required intubation and 23 (3.6%) developed rhabdomyolysis.
• Those who received physostigmine as monotherapy had significantly fewer intubations (OR 0.22, p=0.047) than those who received other treatment regimens.

METHODS
• ToxIC registry data was retrospectively analyzed for patients who exhibited an anticholinergic toxidrome as recorded by the treating physician.
• We recorded what treatment(s) they received for their toxidrome.
• Treatments were classified as physostigmine, benzodiazepines, physostigmine and benzodiazepines, antipsychotics, or no definitive treatment.
• We determined the relative usage of the above medications in patients with an anticholinergic toxidrome.
• Odds ratios were performed on these data to evaluate correlation between adverse events, defined by investigators as rhabdomyolysis or intubation, and the treatments received.

CONCLUSION
• Patients with anticholinergic toxicity were more likely to receive benzodiazepines than physostigmine (28.7% vs 12.4%) as monotherapy.
• A significant number of these patients did not receive benzodiazepines, physostigmine, or antipsychotics for their toxidrome.
• The use of physostigmine as monotherapy was significantly less likely to require intubation (OR 0.22, p=0.047).

LIMITATIONS
• We did not know the order of medication given, or the indications for the medications.
• Centers that participate in the ToxIC Case registry may differ from centers that do not, so our results may not be generalizable.
• Some of the information may be incomplete due to changes in the data form as the registry has evolved.

#13